ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial
Alzheimer's disease (AD) is the most common cause of dementia, causing memory loss and cognitive impairments that interfere with daily life.
A growing body of evidence suggests that impaired brain energy metabolism and mitochondrial dysfunction contribute to cognitive decline in AD.
Trial Overview
The phase 3 clinical trial aims to improve mitochondrial dysfunction by treating patients with the proprietary Combined Metabolic Activator (CMA2) drug.
The trial is taking place across nine clinical centres in Turkey, targeting patients with mild, moderate, and severe symptoms of Alzheimer's disease.
The aim is to improve mitochondrial dysfunction by treating patients with the proprietary Combined Metabolic Activator (CMA2) drug.
Stockholm, Sweden - November 4, 2025 - ScandiBio Therapeutics AB announced the initiation of this multicentre trial, evaluating the efficacy and safety of their pharmaceutical, Combined Metabolic Activator (CMA), in patients with Alzheimer's disease.
Author's summary: ScandiBio initiates phase 3 trial for Alzheimer's treatment.
More News
- Radiohead postpone Copenhagen shows as Thom Yorke battles severe throat infection
- World Champion Zhao Xintong Advances Smoothly to UK Championship Last 16
- Gold Prices Near Diwali Record as Fed Rate-Cut Hopes Boost Demand
- Expansion of Antarctic Bottom Water driven by Antarctic warming in the last deglaciation
- Livestock killed in wind-driven fire that destroyed Ramara barn
- Radiohead postpone Copenhagen concerts after Thom Yorke's throat issues
- Why I Ignore What My Coach Says and Do What I Want in the Gym
- What the Doha Declaration Says (and Doesn't Say) About People Living With HIV
- Investor Relations Overview of Driven Brands Holdings Inc.
- Nigeria’s Economy Expands by 3.98% in Q3, Boosted by Non-Oil Sector